BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy

Core Viewpoint - BioPorto A/S has announced the appointment of Carsten Buhl as the new CEO, effective September 1, 2025, as part of its succession planning strategy [1][2]. Company Leadership Transition - Current CEO Peter Mørch Eriksen will remain in his position until September 1, 2025, and will assist Carsten Buhl during the transition period [2]. - Carsten Buhl has over 25 years of experience in the MedTech/life science industries, previously serving as President of Americas at WSAudiology and holding senior leadership roles at Natus Medical Inc, Ambu, and GN Store Nord [3]. Strategic Goals and Future Plans - Jens Due Olsen, Chair of BioPorto, emphasized that Carsten Buhl will play a crucial role in launching ProNephro AKI (NGAL)™ in the US market, driving revenue growth, and finalizing clinical studies for an FDA application for adult use in 2026 [4]. - Carsten Buhl expressed enthusiasm about joining BioPorto and aims to unlock the full potential of the company's biomarker tests for kidney health, which can enhance clinical and economic outcomes globally [4]. Company Achievements - Under Peter Mørch Eriksen's leadership, BioPorto achieved significant milestones, including the development of a comprehensive Corporate Strategy Plan, revenue growth, preparation for the commercial launch of ProNephro AKI (NGAL) in the US, and securing critical financing rounds [4]. Company Overview - BioPorto specializes in in vitro diagnostics, focusing on actionable biomarkers to improve patient management and outcomes [5]. - The company's flagship products utilize the NGAL biomarker to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), enabling earlier intervention and tailored patient management strategies [6].